We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Questions Sarepta Therapy’s Benefit in DMD After BioMarin Loss
FDA Questions Sarepta Therapy’s Benefit in DMD After BioMarin Loss
With BioMarin’s Duchenne muscular dystrophy candidate drisapersen failing to garner FDA approval this week, a competitor close on its heels also is facing questions from the agency over whether it offers any benefit.